Ginkgo 10-Q: Q3 Loss Narrows to $41M, $285M Liquidity Funds 12+ Months
DNA has more than doubled off its 52-week low of $5.37.
Summary
Ginkgo's Q3 10-Q shows the net loss narrowing to $41.0M from $80.8M on cost cuts, with $285.4M of cash and securities the company says covers at least 12 months of operations.
Key Events · Earnings and Guidance · DNA
-
Q3 Loss Nearly Halved
Net loss was $41.0M versus $80.8M a year ago, as R&D fell to $40.9M from $69.4M and G&A to $28.6M from $37.0M.
-
Liquidity Covers 12 Months
Cash and cash equivalents of $84.5M plus $200.9M of marketable securities total $285.4M, which management says funds projected operations through at least the next 12 months.
-
Restricted Balances Jump
Restricted cash and marketable securities, non-current rose to $84.2M from $38.1M at December 31, 2025, shrinking the truly liquid pool.
-
ATM Drip Continues
2.7M Class A shares were sold for $23.0M net in the first nine months; $41.1M of net proceeds has been raised since the $100.0M Sales Agreement began.
Analysis · DNA · Life Sciences
The headline numbers were already out on November 5, but the 10-Q is where the balance sheet gets audited-level scrutiny. Cash and cash equivalents fell to $84.5M from $167.2M at year-end, yet total liquidity of $285.4M (including $200.9M of marketable securities) is stated to fund operations through at least the next 12 months — that removes near-term financing risk even as the company keeps leaning on its ATM. The offset is that $84.2M of restricted cash and securities now sits outside that liquid pool, up from $38.1M, and the company still burned $117.0M of operating cash in nine months. Cost cuts are real: R&D fell to $40.9M from $69.4M and G&A to $28.6M from $37.0M, which is why the quarterly loss nearly halved.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DNA was trading at $12.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $833M. The 52-week trading range was $5.37 to $18.22. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.